282 results on '"Peyvandi F."'
Search Results
2. Hemostatic abnormalities in patients with Ehlers–Danlos syndrome
3. Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes
4. An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS‐VWF study
5. Recombinant factor XIII A‐subunit in a patient with factor XIII deficiency and recurrent pregnancy loss
6. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement
7. Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency
8. Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis
9. Minimal factor XIII activity level to prevent major spontaneous bleeds
10. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies
11. Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura
12. Pregnancy outcome after a first episode of cerebral vein thrombosis
13. Advances in the treatment of bleeding disorders
14. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin‐independent impairment of the thrombin‐activatable fibrinolysis inhibitor pathway
15. A critical appraisal of one‐stage and chromogenic assays of factor VIII activity
16. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination
17. Plasma ADAMTS‐13 levels and the risk of myocardial infarction: an individual patient data meta‐analysis
18. Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa and p.Gly366Ser, fibrinogen Beograd) impacting on the fibrinogen γ‐module
19. Design of clinical trials for new products in hemophilia: communication from the SSC of the ISTH
20. Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels
21. Measurement and prevalence of circulating ADAMTS13‐specific immune complexes in autoimmune thrombotic thrombocytopenic purpura
22. The ISTH Bleeding Assessment Tool and the risk of future bleeding
23. The type 2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress
24. Next‐generation sequencing study finds an excess of rare, coding single‐nucleotide variants of ADAMTS13 in patients with deep vein thrombosis
25. A synonymous (c.3390C>T) or a splice‐site (c.3380‐2A>G) mutation causes exon 26 skipping in four patients with von Willebrand disease (2A/IIE)
26. Future of coagulation factor replacement therapy
27. Minimal dataset for post‐registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH
28. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity
29. ADAMTS‐13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura
30. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders
31. Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission
32. Fibrinogen replacement therapy for congenital fibrinogen deficiency
33. Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTS‐13
34. Gynecological and obstetrical manifestations of inherited bleeding disorders in women
35. Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes
36. Factor XIII – an under diagnosed deficiency – are we using the right assays?
37. The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease
38. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura
39. ADAMTS‐13 assays in thrombotic thrombocytopenic purpura
40. Pharmacokinetics and safety of fibrinogen concentrate
41. Identification of new genetic risk factors for venous thrombosis by targeted sequencing: results of the MILES study: OR394
42. Recurrence and mortality in young women with myocardial infarction or ischemic stroke: 19-year follow-up of the risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: OR255
43. High throughput amino acid sequence epitope mapping of inhibitory antibodies in severe hemophilia A: OR108
44. Genome editing of factor X in zebrafish reveals unexpected early survival and late onset hemorrhage: OR039
45. Acquired von willebrand syndrome and response to desmopressin: OR026
46. Platelet mitochondrial dysfunction in patients with sepsis or cardiogenic shock: OR005
47. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B
48. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS‐13)
49. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No
50. The EAHAD coagulation factor variant databases: GH05
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.